
price data provid thomson reuter
number may add due round
remain outperform rate rais target follow releas
document issu market close
disclos compani reach settlement agreement
ipr proceed patent issu extend soliri exclus
invalid three patent could shorten exclus composit
matter patent expir settlement permit launch
biosimilar march see favor time target
move increas valuat multipl
settlement agreement afford clariti addit time
execut ultomiri diversif strategi
alxn/amgn enter soliri ipr settlement agreement file
issu close friday announc reach settlement
agreement three ipr proceed relat soliri see link
file file motion us patent trial
appeal board ptab dismiss proceed three point
certainti beauti thing file limit detail
notabl agreement call entri soliri biosimilar product
effect motion dismiss must grant
ptab termin proceed patent attorney consult daniel
ravich previous note ipr proceed occur
earlier ipr document presag deal detail recal previous
report ipr file compani indic agreement reach
principl see note addit time would necessari
work detail upcom oral argument ptab
re-schedul oral argument set begin patent attorney
consult anticip quick closur deal look like
exactli transpir
dahlia still need finish abp eculizumab biosimilar
current evalu pivot studi known dahlia link studi
note march primari complet time studi shift
septemb chang appear made prior
relat disrupt affect space bottom line complet
studi still necessari biosimilar launch
rais target remain outperform soliris/ultomiri revenu
estim remain unchang settlement agreement
necessarili preclud challeng think offer suffici time
execut ultomiri expans diversif strategi
deriv target via multipl previous non-gaap
ep estim discount back per year
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
wedbush view remain outperform rate rais target follow
releas document issu market close disclos
compani reach settlement agreement ipr proceed
patent issu extend soliri exclus invalid three patent could
shorten exclus composit matter patent expir settlement
permit launch biosimilar march see favor time
target move increas valuat multipl
settlement agreement afford clariti addit time execut
what new reach settlement agreement ipr proceed
file issu close friday announc reach settlement
agreement three ipr proceed relat soliri file
motion us patent trial appeal board ptab dismiss proceed
file limit detail notabl agreement call entri soliri
biosimilar product effect motion dismiss must grant ptab
termin proceed patent attorney consult daniel ravich previous
note ipr proceed occur
recal previous report ipr file compani indic agreement
reach principl addit time would necessari work detail upcom
oral argument ptab re-schedul oral argument set begin
patent attorney consult anticip quick closur deal look like exactli
transpir
implic
anticip detail settlement term emerg subsequ report
howev see time posit three patent involv
ipr proceed extend soliri exclus composit matter
patent soliri set expir thu settlement effect trim
proport out-year think suffici continu execut
ultomiri diversif strategi pipelin effort note ultomiri
repres complement franchis revenu think ultomiri format
particularli use addit indic myasthenia gravi
compani abp eculizumab biosimilar current evalu
pivot studi known dahlia note march primari complet time studi
shift septemb first time time extend
recent chang appear made prior disrupt
affect broader space entrant emerg pnh space wonder
feasibl complet enrol biosimilar trial bottom line complet
studi still necessari biosimilar launch
estim soliris/ultomiri complement franchis remain unchang point
overhang lift increas valuat multipl
appli non-gaap ep estim discount back per year increas
target shown figur multipl in-lin
large-cap peer group current trade consensu ep estim
incom statement ms
good sold
 expens revenu
sg expens revenu
target deriv multipl ep discount back discount vs large-cap
consensu ep due current headwind
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori alexion employ acceler strategi gain approv market product regul may requir
addit data could alter requir approv necessit addit longer studi failur gain product
label lack certain featur could limit alexion abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti regeneron achillion competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur alexion exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
may
may
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
